skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension

Review

(1543) Views  (541) Full article downloads

Authors: Nicholas P Bell, José L Ramos, Robert M Feldman

Published Date November 2010 Volume 2010:4 Pages 1331 - 1346
DOI: http://dx.doi.org/10.2147/OPTH.S14054

Nicholas P Bell, José L Ramos, Robert M Feldman
Robert Cizik Eye Clinic, Department of Ophthalmology and Visual Science, The University of Texas Medical School at Houston, Houston, Texas 77030, USA

Abstract: Glaucoma is a collection of diseases characterized by multifactorial progressive changes leading to visual field loss and optic neuropathy most frequently due to elevated intraocular pressure (IOP). The goal of treatment is the lowering of the IOP to prevent additional optic nerve damage. Treatment usually begins with topical pharmacological agents as monotherapy, progresses to combination therapy with agents from up to 4 different classes of IOP-lowering medications, and then proceeds to laser or incisional surgical modalities for refractory cases. The fixed combination therapy with the carbonic anhydrase inhibitor dorzolamide hydrochloride 2% and the beta blocker timolol maleate 0.5% is now available in a generic formulation for the treatment of patients who have not responded sufficiently to monotherapy with beta adrenergic blockers. In pre- and postmarketing clinical studies, the fixed combination dorzolamide–timolol has been shown to be safe and efficacious, and well tolerated by patients. The fixed combination dorzolamide–timolol is convenient for patients, reduces their dosing regimen with the goal of increasing their compliance, reduces the effects of “washout” when instilling multiple drops, and reduces the preservative burden by reducing the number of drops administered per day.

Keywords: dorzolamide, timolol, glaucoma, ocular hypertension, elevated IOP, fixed combination therapy






Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
Erratum - Intracellular heavy metal nanoparticle storage
Erratum
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?